Remdesivir News and Research

RSS

Favipiravir does not attenuate the progression of COVID-19

Scientists have conducted an observational study to evaluate the efficacy of an anti-influenza medicine favipiravir in treating hospitalized COVID-19 patients.

11 Dec 2020

Researchers use AI platform to identify best combination of available therapies against COVID-19.

A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

11 Dec 2020

Using AI to find optimal combination of available therapies against SARS-CoV-2

A team of researchers from the National University of Singapore has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

10 Dec 2020

A battle-weary Seattle hospital fights the latest COVID surge

As hospitals across the country weather a surge of COVID-19 patients, in Seattle — an early epicenter of the outbreak — nurses, respiratory therapists and physicians are staring down a startling resurgence of the coronavirus that’s expected to test even one of the best-prepared hospitals on the pandemic’s front lines.

10 Dec 2020

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

Molecular simulations reveal that remdesivir targets two SARS-CoV-2 enzymes

Remdesivir has been shown to target both RNA-dependent RNA polymerase and main protease of SARS-CoV-2 – resulting in a ‘double whammy’ effect.

7 Dec 2020

Can melatonin help prevent severe COVID-19?

A team of researchers at the University of Toronto in Canada has found that melatonin can be an adjuvant to augment the efficacy of anti-SARS-CoV-2 vaccines. They believe that the drug is a potential “silver bullet” to combat the COVID-19 pandemic.

3 Dec 2020

Study: Infants diagnosed with COVID-19 experienced reversible myocardial injury, heart failure

A 2-month-old infant diagnosed with COVID-19 experienced reversible myocardial injury and heart failure, similar to COVID-19 related heart issues seen in adults, according to a case published in JACC: Case Reports.

3 Dec 2020

Research suggests plant flavonols could serve as effective antivirals for SARS-CoV-2

Researchers in Algeria have reviewed some of the evidence suggesting that flavonols commonly found in many plants and vegetables could be used as a therapeutic approach to coronavirus disease 2019 (COVID-19).

1 Dec 2020

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

3D8, a 27-kDa recombinant antibody fragment, was found in autoimmune-prone Murphy Roths Large mice. The single-chain variable fragment (scFv) has the nucleic acid hydrolyzing activity and is shown to degrade DNA or mRNA of viruses in infected cells.

30 Nov 2020

Resveratrol shows potential as SARS-CoV-2 antiviral, study finds

A recent study reveals that resveratrol, a phenolic compound produced by spermatophytes, can inhibit the viral replication SARS-CoV-2.

27 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

Mefloquine shows potential as anti-SARS-CoV-2 drug

A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.

24 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Remdesivir News and Research

Favipiravir does not attenuate the progression of COVID-19

Researchers use AI platform to identify best combination of available therapies against COVID-19.

Using AI to find optimal combination of available therapies against SARS-CoV-2

A battle-weary Seattle hospital fights the latest COVID surge

Amilorides reduce SARS-CoV-2 viral replication in vitro

Molecular simulations reveal that remdesivir targets two SARS-CoV-2 enzymes

Can melatonin help prevent severe COVID-19?

Study: Infants diagnosed with COVID-19 experienced reversible myocardial injury, heart failure

Research suggests plant flavonols could serve as effective antivirals for SARS-CoV-2

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

Resveratrol shows potential as SARS-CoV-2 antiviral, study finds

Early interferon therapy may mitigate COVID-19 severity

Mefloquine shows potential as anti-SARS-CoV-2 drug

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Scientists exploit 'trojan horse' feature in SARS-CoV-2 virus to create antivirals against COVID-19

Study finds more than half of in-hospital COVID-19 deaths among Black, Hispanic patients

Researchers report encouraging results from in vitro combination therapy against COVID-19

Antifungal agent Itraconazole inhibits SARS CoV-2 in vitro

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News